Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company, Thursday reported first-quarter net loss of $29.8 million or $0.20 per share, compared to $47.5 million or $0.33 per share for the same period in 2024.
Revenue was $52.4 million for the quarter, representing a 25% increase from $41.9 million in the first quarter in the prior year.
MRD revenue was $43.7 million for the quarter, representing a 34% increase from the first quarter in the prior year. Immune Medicine revenue was $8.7 million for the quarter, representing a 6% decrease from the first quarter in the prior year.
Adaptive Biotechnologies expects full year revenue for the MRD business to be between $180 million and $190 million, updated from the previous range between $175 million and $185 million. No revenue guidance is provided for the Immune Medicine business.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.